Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Page 1
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
Campagna MP, Havrdova EK, Horakova D, Izquierdo G, Matesanz F, Eichau S, Lechner-Scott J, Taylor BV, García-Sanchéz MI, Alcina A, van der Walt A, Butzkueven H, Jokubaitis VG. Campagna MP, et al. Among authors: izquierdo g. Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406. Online ahead of print. Mult Scler. 2024. PMID: 38511853 Free article.
CONCLUSION: These findings highlight the complexity of genetic factors mediating long-term MS outcomes and the need for further research....
CONCLUSION: These findings highlight the complexity of genetic factors mediating long-term MS outcomes and the need for further resea …
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, Skibina O, Kuhle J, Hodgkinson S, Boz C, Alroughani R, Lechner-Scott J, Barnett M, Izquierdo G, Prat A, Horakova D, Kubala Havrdova E, Macdonell R, Patti F, Khoury SJ, Slee M, Karabudak R, Onofrj M, Van Pesch V, Prevost J, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. Zhu C, et al. Among authors: izquierdo g. J Neurol Neurosurg Psychiatry. 2022 Dec;93(12):1330-1337. doi: 10.1136/jnnp-2022-330104. Epub 2022 Oct 19. J Neurol Neurosurg Psychiatry. 2022. PMID: 36261289
Due to the low ARRs in all three treatment groups, additional observation time is required to determine if statistical difference in ARRs results in long-term disability differences....
Due to the low ARRs in all three treatment groups, additional observation time is required to determine if statistical difference in ARRs re …
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, Alroughani R, Boz C, Shaygannejad V, van Pesch V, Cartechini E, Kappos L, Lechner-Scott J, Bergamaschi R, Turkoglu R, Solaro C, Iuliano G, Granella F, Van Wijmeersch B, Spitaleri D, Slee M, McCombe P, Prevost J, Ampapa R, Ozakbas S, Sanchez-Menoyo JL, Soysal A, Vucic S, Petersen T, de Gans K, Butler E, Hodgkinson S, Sidhom Y, Gouider R, Cristiano E, Castillo-Triviño T, Saladino ML, Barnett M, Moore F, Rozsa C, Yamout B, Skibina O, van der Walt A, Buzzard K, Gray O, Hughes S, Sempere AP, Singhal B, Fragoso Y, Shaw C, Kermode A, Taylor B, Simo M, Shuey N, Al-Harbi T, Macdonell R, Dominguez JA, Csepany T, Sirbu CA, Sormani MP, Butzkueven H, Kalincik T. Sharmin S, et al. Among authors: izquierdo g. Eur J Neurol. 2022 Aug;29(8):2321-2334. doi: 10.1111/ene.15406. Epub 2022 Jun 9. Eur J Neurol. 2022. PMID: 35582938 Free PMC article.
BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. ...CONCLUSIONS: Clinicodemographic characteri …
BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); howeve …
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.
Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, Kubala Havrdová E, Grand'Maison F, Prat A, Girard M, Hupperts R, Onofrj M, Lugaresi A, Taylor B; MSBase Study Group; Giovannoni G, Kappos L, Hauser SL, Montalban X, Craveiro L, Freitas R, Model F, Overell J, Muros-Le Rouzic E, Sauter A, Wang Q, Wormser D, Wolinsky JS. Butzkueven H, et al. Among authors: izquierdo g. Eur J Neurol. 2022 Apr;29(4):1082-1090. doi: 10.1111/ene.14824. Epub 2021 May 6. Eur J Neurol. 2022. PMID: 33724638 Free PMC article. Clinical Trial.
Here we (i) assess the effect of ocrelizumab on time to EDSS 7.0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP), (ii) quantify likely long-term benefits by extrapolating results, and (iii) assess the plausibility of extrapolations us …
Here we (i) assess the effect of ocrelizumab on time to EDSS 7.0 over the ORATORIO (NCT01194570) double-blind and extended controlled period …
Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).
Pérez-Miralles F, Prefasi D, García-Merino A, Ara JR, Izquierdo G, Meca-Lallana V, Gascón-Giménez F, Martínez-Ginés ML, Ramió-Torrentà L, Costa-Frossard L, Fernández Ó, Moreno-García S, Medrano N, Maurino J, Casanova B. Pérez-Miralles F, et al. Among authors: izquierdo g. Mult Scler Relat Disord. 2021 May;50:102860. doi: 10.1016/j.msard.2021.102860. Epub 2021 Feb 23. Mult Scler Relat Disord. 2021. PMID: 33647591
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand'Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermode A, Csepany T, Singhal B, Shuey N, Piroska I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study Group. Kalincik T, et al. Among authors: izquierdo g. Neurology. 2021 Feb 2;96(5):e783-e797. doi: 10.1212/WNL.0000000000011242. Epub 2020 Dec 28. Neurology. 2021. PMID: 33372028 Free PMC article.
OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. ...This study provides evidence that disease-modifying therapies are effective in improving …
OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we …
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Larochelle C, Alroughani R, Bergamaschi R, Sola P, Ferraro D, Grammond P, Grand' Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T. Le M, et al. Among authors: izquierdo g. Mult Scler. 2021 Apr;27(5):755-766. doi: 10.1177/1352458520926955. Epub 2020 Jun 15. Mult Scler. 2021. PMID: 32538713
BACKGROUND: Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values remain unclear. OBJECTIVE: The aim of this study was to investigate long-term disability outcomes in patients with early cerebellar and brainstem …
BACKGROUND: Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values remain uncle …
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Barrero F, Mallada-Frechin J, Martínez-Ginés ML, Marzo ME, Meca-Lallana V, Izquierdo G, Ara JR, Oreja-Guevara C, Meca-Lallana J, Forero L, Sánchez-Vera I, Moreno MJ; in representation of the MS NEXT study investigators. Barrero F, et al. Among authors: izquierdo g. PLoS One. 2020 Apr 2;15(4):e0230846. doi: 10.1371/journal.pone.0230846. eCollection 2020. PLoS One. 2020. PMID: 32240213 Free PMC article.
The analysis of patients who received fingolimod in routine clinical practice confirmed adequate efficacy and safety, even for long-term treatment. The present data also confirmed the positive benefit/risk balance with fingolimod in real-world clinical practice setting....
The analysis of patients who received fingolimod in routine clinical practice confirmed adequate efficacy and safety, even for long-term …
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T; MSBase study group. He A, et al. Among authors: izquierdo g. Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199096
We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore aimed to compare long-term disability outcomes between patients who started high-efficacy therapies within 2 years of disease onset w …
We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore …
[Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
Oreja-Guevara C, García-Merino JA, Saiz A, Rodríguez-Antigüedad A, Álvarez-Cermeño JC, Estrada-Pérez V, Izquierdo G, Fernández O. Oreja-Guevara C, et al. Among authors: izquierdo g. Rev Neurol. 2019 Dec 17;69(s02):1-9. doi: 10.33588/rn.69s02.2019380. Rev Neurol. 2019. PMID: 31933293 Review. Spanish.
Results of clinical trials have demonstrated the safety, tolerability and long-term efficacy of cladribine tablets in patients with recurring multiple sclerosis. ...In terms of safety, the treated patients had a higher frequency of lymphopenia, in relation to its mechanism …
Results of clinical trials have demonstrated the safety, tolerability and long-term efficacy of cladribine tablets in patients with r …
30 results